ashby
$236,708–$260,200 / year
Posted 3 weeks ago
Salary: $224,452–$245,500 / year
Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
The Director, Commercial Learning & Field Enablement is responsible for defining and delivering a comprehensive commercial learning strategy that builds field capability, supports launch readiness, and enables sustained commercial performance across Xenon’s U.S. organization.
This role owns the design, development, and delivery of all commercial training programs, ensuring field teams are equipped with the knowledge, skills, and behaviors required to execute effectively. The Director will build and scale a best-in-class learning ecosystem, integrating functional training, leadership development, and enterprise training to support both immediate launch needs and long-term capability building.
Acting as a strategic partner across Sales, Marketing, Market Access, Medical, Commercial Operations, and Human Resources, this role translates commercial strategy into structured, role-specific learning programs that enable field readiness and performance.
This position reports to the Senior Director, Field Strategy & Enablement and is a key member of the extended commercial leadership team. This position will be remote.
Commercial Learning Strategy & Execution
Commercial Leadership Development
Training Design & Delivery
Commercial Meetings & Learning Integration
Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance programs, Employee Assistance Program, travel insurance, and retirement savings programs with company matching contributions.
Xenon encourages time to rest and re-charge through vacation, personal days, sick days, and an end-of-year company shutdown. Xenon highly values employee development and has an expanding Training, Learning & Development program, including a Tuition Assistance program for advanced degrees.